Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The teams will assist the state health authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
Acquisition expands Merck’s growing hematology portfolio
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Subscribe To Our Newsletter & Stay Updated
